MMP2、MMP9、Galectin-3、CK19、及Ret在甲状腺滤泡型肿瘤中的表达

Expression of MMP2, MMP9, Galectin-3, CK19 and Ret in follicular thyroid tumors

目的 探讨MMP2、MMP9、Galectin 3、CK19和Ret在甲状腺良、恶性滤泡型肿瘤中的表达情况 ,以及其在病理诊断中的价值。方法 运用免疫组化方法检测 35例甲状腺滤泡癌、36例甲状腺腺瘤MMP2、MMP9、Galectin 3、CK19和Ret的表达情况。结果 MMP2和MMP9在甲状腺滤泡癌表达阳性率为 10 0 % ,而在甲状腺腺瘤中表达分别为 2 7.8%及 4 7.2 % ,二者在良、恶性肿瘤的表达差异极显著 (P <0 .0 1)。Galectin 3表达阳性率分别为 4 8.6 %及13.9% (P <0.0 5 )。CK19在甲状腺滤泡癌中阳性有所增高 ,但与腺瘤比较表达无差异。Ret几乎不在甲状腺滤泡型肿瘤中表达。同时观察 15例甲状腺滤泡癌癌旁组织 ,5种蛋白均不表达或表达甚少。结论 MMP2、MMP9及Galectin-3在恶性甲状腺滤泡型肿瘤中的表达高于良性 ,可能三者与促进甲状腺滤泡型肿瘤的浸润机制有关 ,其免疫组化染色虽无绝对特异性 。

Objective To investigate the expression of MMP2, MMP9, galectin-3, CK19 and Ret in follicular thyroid tumors including follicular thyroid carcinoma (FTC) and follicular thyroid adenoma (FTA) and their pathological diagnosis value. Methods A total of 35 cases of FTC and 36 cases of FTA were enrolled into the study. Immunohistochemistry for MMP2, MMP9, galectin-3, CK19 and Ret was performed in all of cases. Results The positive rates for MMP2 and MMP9 in FTC were 100%, which were significantly higher than those in FTA (27.8% and 47.2% respectively) (P<0.001) . The positive rates for galectin-3 in FTC and FTA were 48.6% and 13.9% respectively (P<0.005). The expression of CK19 in FTC was higher than that in FTA, but there was no obvious difference between them. Almost there was no expression of Ret in follicular thyroid tumors. Moreover, 15 cases of paracarcinoma tous tissue were observed. There was no or week expression of the five proteins. Conclusion The expression of MMP2, MMP9 and galectin-3 is significantly higher in FTC than in FTA. They may play some role in invasion of follicular thyroid tumors, and have other more important diagnosis values.